End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.

Vural Ozdemir1,*, Erik Fisher2, Edward S. Dove1, Hilary Burton3, Galen E. B. Wright4, Mario Masellis5,*, and Louise Warnich4,* 1Centre of Genomics and Policy, Department of Human Genetics, Faculty of Medicine, McGill University, Montreal, QC, Canada 2School of Politics and Global Studies, Consortium for Science, Policy & Outcomes, Center for Nanotechnology in Society, College of Liberal Arts and Sciences, Arizona State University, Tempe, AZ, USA 3Foundation for Genomics and Population Health, 2 Worts Causeway, Cambridge, UK 4Department of Genetics, Stellenbosch University, Stellenbosch, South Africa 5L.C. Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Department of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

[1]  Rekha Jain,et al.  Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology. , 2011, Current pharmacogenomics and personalized medicine.

[2]  Erik Fisher,et al.  Editorial Overview - Public Science and Technology Scholars: Engaging Whom? , 2011, Sci. Eng. Ethics.

[3]  W. Kalow,et al.  Pharmacogenetics in perspective. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  Damian Smedley,et al.  Sustaining the Data and Bioresource Commons , 2010, Science.

[5]  L. Hood,et al.  Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine , 2012, Journal of internal medicine.

[6]  A. Motulsky.  Drug reactions enzymes, and biochemical genetics. , 1957, Journal of the American Medical Association.

[7]  Michael Gibbons,et al.  Introduction: `Mode 2' Revisited: The New Production of Knowledge , 2003 .

[8]  Yann Joly,et al.  Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA). , 2011, Current pharmacogenomics and personalized medicine.

[9]  M. Khoury.  Interview: Dr. Muin J. Khoury Discusses the Future of Public Health Genomics and why it Matters for Personalized Medicine and Global Health , 2009 .

[10]  Muin J. Khoury,et al.  The path from genome-based research to population health: Development of an international public health genomics network , 2006, Genetics in Medicine.

[11]  B. Pulendran,et al.  Systems vaccinomics: the road ahead for vaccinology. , 2011, Omics : a journal of integrative biology.

[12]  P. Harrison,et al.  Curiosity, Forbidden Knowledge, and the Reformation of Natural Philosophy in Early Modern England , 2001, Isis.

[13]  Pharmacogenomics and Public Health , 2009, Public Health Genomics.

[14]  M. Weatherall.  Heredity and Response to Drugs , 1963 .

[15]  A. Hedgecoe,et al.  Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics , 2003 .

[16]  M. Pepper,et al.  Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation , 2011, Current pharmacogenomics and personalized medicine.

[17]  W. Kalow.  Pharmacogenetics : heredity and the response to drugs , 1962 .

[18]  V. O. A. T. Someya.  Editorial [A Transdisciplinary Forum for Study of Individual and Population Variability in Response to Health Interventions and Personalized Medicine] , 2009 .

[19]  Eugene Kolker,et al.  Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. , 2009, Omics : a journal of integrative biology.

[20]  R. Zimmern.  Genomics and individuals in public health practice: are we luddites or can we meet the challenge? , 2011, Journal of public health.

[21]  Clement Adebamowo,et al.  Editorial (An Idea Whose Time Has Come? An African Foresight Observatory on Genomics Medicine and Data-Intensive Global Science) , 2012 .

[22]  I. Kickbusch.  Health Governance: The Health Society , 2007 .

[23]  D. Easton,et al.  Polygenic susceptibility to prostate and breast cancer: implications for personalised screening , 2011, British Journal of Cancer.

[24]  B K Tang,et al.  The science of pharmacological variability: An essay , 1999, Clinical pharmacology and therapeutics.

[25]  Nina V Fedoroff.  The Global Knowledge Society , 2012, Science.

[26]  Pierre Bourdieu,et al.  Outline of a Theory of Practice , 2020, On Violence.

[27]  P. Bourdieu,et al.  实践与反思 : 反思社会学导引 = An invitation to reflexive sociology , 1994 .

[28]  Pascale Lehoux,et al.  Editorial (Moving Beyond Our Mutual Ignorance. Or, How would Engaging the Public Benefit the Personalized Medicine Community?) , 2011 .

[29]  John N Lavis,et al.  Examining the role of health services research in public policymaking. , 2002, The Milbank quarterly.

[30]  Jean-Louis Denis,et al.  Beyond evidence: the micropolitics of improvement , 2011, Quality and Safety in Health Care.

[31]  F. Vogel.  Moderne Probleme der Humangenetik , 1959 .

[32]  Bridget M Kuehn.  Genomics illuminates a deadly brain cancer. , 2010, JAMA.

[33]  B. Lerer,et al.  Pharmacogenomics and the Promise of Personalized Medicine , 2005 .

[34]  Wish fulfilment and its discontents , 2003, EMBO reports.

[35]  Claire Marris,et al.  Open Engagement: Exploring Public Participation in the Biosciences , 2010, PLoS biology.

[36]  Vural Ozdemir,et al.  Asia-Pacific Health 2020 and Genomics without Borders: Co-Production of Knowledge by Science and Society Partnership for Global Personalized Medicine. , 2011, Current pharmacogenomics and personalized medicine.